It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Arsenic enhances the carcinogenicity of ultraviolet radiation (UVR). However, the mechanisms of arsenic-driven oncogenesis are not well understood. Here, we utilize experimental systems to investigate the carcinogenic and mutagenic properties of co-exposure to arsenic and UVR. In vitro and in vivo exposures indicate that, by itself, arsenic is not mutagenic. However, in combination with UVR, arsenic exposure has a synergistic effect leading to an accelerated mouse skin carcinogenesis and to more than 2-fold enrichment of UVR mutational burden. Notably, mutational signature ID13, previously found only in UVR-associated human skin cancers, is observed exclusively in mouse skin tumors and cell lines jointly exposed to arsenic and UVR. This signature was not observed in any model system exposed purely to arsenic or purely to UVR, making ID13, to the best of our knowledge, the first co-exposure signature to be reported using controlled experimental conditions. Analysis of existing skin cancer genomics data reveals that only a subset of cancers harbor ID13 and these exhibit an elevated UVR mutagenesis. Our results report a unique mutational signature caused by a co-exposure to two environmental carcinogens and provide comprehensive evidence that arsenic is a potent co-mutagen and co-carcinogen of UVR.
Arsenic and ultraviolet radiation (UVR) are potent carcinogens. This study shows that a co-exposure to both arsenic and UVR leads to an accelerated mouse skin carcinogenesis due to an enhanced accumulation of UVR-associated somatic mutations.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of New Mexico, Department of Pharmaceutical Sciences, College of Pharmacy, Albuquerque, USA (GRID:grid.266832.b) (ISNI:0000 0001 2188 8502)
2 Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); Moores Cancer Center, UC San Diego, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); Department of Bioengineering, UC San Diego, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
3 Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA (GRID:grid.419791.3) (ISNI:0000 0000 9902 6374)
4 University of New Mexico, Department of Pharmaceutical Sciences, College of Pharmacy, Albuquerque, USA (GRID:grid.266832.b) (ISNI:0000 0001 2188 8502); Stony Brook Cancer Center, Stony Brook University, Stony Brook, USA (GRID:grid.36425.36) (ISNI:0000 0001 2216 9681); Stony Brook University School of Medicine, Department of Pathology, Stony Brook, USA (GRID:grid.36425.36) (ISNI:0000 0001 2216 9681)